Literature DB >> 20447519

Epidermolysis bullosa care in Scandinavia.

Anders Vahlquist1, Kaisa Tasanen.   

Abstract

The recessive forms of epidermolysis bullosa (EB) are common in Scandinavia, especially in the northern parts of Norway and Sweden. The daily care of EB in Scandinavia is organized around the patient via settings at the local hospital or health service. However, the diagnosis of EB and providing correct patient/family information usually require a specialized service. Specialized EB care in Scandinavia is mainly provided by dermatologists, pediatricians, and dentists working together in a team. The increasing number of EB families with foreign ethnic backgrounds and language problems is a challenge to the health service, especially in Sweden, and demands increased facilities. Also, the high expectations by parents of children with junctional EB and recessive dystrophic EB about new, revolutionizing therapies are challenges that can only be met by international collaboration and more research in specialized centers for EB. A close collaboration with patient organizations and various charity organizations will be very helpful in this respect. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20447519     DOI: 10.1016/j.det.2010.02.018

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  2 in total

1.  A consensus approach to wound care in epidermolysis bullosa.

Authors:  Elena Pope; Irene Lara-Corrales; Jemima Mellerio; Anna Martinez; Gregory Schultz; Robert Burrell; Laurie Goodman; Patricia Coutts; John Wagner; Upton Allen; Gary Sibbald
Journal:  J Am Acad Dermatol       Date:  2012-03-02       Impact factor: 11.527

2.  Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?

Authors:  R Baardman; V K Yenamandra; J C Duipmans; A M G Pasmooij; M F Jonkman; P C van den Akker; M C Bolling
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-11-16       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.